From the floor in Shenzhen: 19 posters, one theme
Reported from the sessions, and from the two hours afterwards.
April 2024 — Vol. 1, No. 4
Page 4 of 4 of this archive, newest first.
Also filed — page 4
the rolling newsroom, April 2024Spain pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
VendorInvestigate result on a Changsha dulaglutide lot lands 3.5 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Halvard & Pike Apothecary of Portland, Maine closes after 19 years
A proper account of an operation that existed, and of what closing it cost.
Norway declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
BCH declines, for the 6th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 10-day notice: how a compounding wind-down works in Mexico
The document is four pages. Three of them are about dates.
Singapore caps tirzepatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-OSA extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 24 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a SWB dulaglutide lot at 96.2%, against 95.6% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
From the floor in Xianning: 17 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What a 29% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.